Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C. Galmarini CM, et al. Among authors: bernard marty c. Clin Cancer Res. 2008 Jul 15;14(14):4511-6. doi: 10.1158/1078-0432.CCR-07-4741. Clin Cancer Res. 2008. PMID: 18628466 Clinical Trial.
Management of head and neck cancer in elderly patients.
Lalami Y, de Castro G Jr, Bernard-Marty C, Awada A. Lalami Y, et al. Among authors: bernard marty c. Drugs Aging. 2009;26(7):571-83. doi: 10.2165/11316340-000000000-00000. Drugs Aging. 2009. PMID: 19655824 Review.
[Systemic treatment of brain metastases from breast cancer].
Taillibert S, Conforti R, Bonneterre J, Bachelot T, Le Rhun E, Bernard-Marty C. Taillibert S, et al. Among authors: bernard marty c. Cancer Radiother. 2015 Feb;19(1):36-42. doi: 10.1016/j.canrad.2014.12.003. Epub 2015 Feb 7. Cancer Radiother. 2015. PMID: 25662600 Review. French.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
26 results